A Bacterial Pathogen Co-opts Host Plasmin to Resist Killing by Cathelicidin Antimicrobial Peptides

Andrew Hollands¹, David Gonzalez¹, Emma Leire¹, Cortny Donald⁵, Richard L. Gallo¹³, Martina Sanderson-Smith⁵, Pieter C. Dorrestein²⁴, Victor Nizet¹²*

¹Department of Pediatrics, ²Skaggs School of Pharmacy and Pharmaceutical Sciences, ³Department of Medicine, ⁴Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California;
⁵Illawarra Health and Medical Research Institute and School of Biological Sciences, University of Wollongong, Wollongong, New South Wales, Australia;

*Running title: Streptokinase-activated plasmin degrades cathelicidin AMPs

To whom correspondence should be addressed: Dr. Victor Nizet, Division of Pediatric Pharmacology & Drug Discovery, University of California, San Diego, 9500 Gilman Drive, Mail Code 0687, La Jolla, CA 92093, USA, Tel: (858) 534-7408, Fax: (858) 534-5611, email: vnizet@ucsd.edu

Keywords: Group A Streptococcus, Streptococcus pyogenes, streptokinase, plasmin, cathelicidin, LL-37, antimicrobial peptides

Background: Group A Streptococcus (GAS) produces streptokinase (Ska), which activates plasminogen to plasmin while binding the host enzyme to the bacterial surface.

Results: Ska-activated plasmin can degrade human cathelicin LL-37, promoting GAS resistance to the antimicrobial peptide.

Conclusion: Ska contributes to GAS innate immune evasion and virulence.

Significance: A human pathogen can co-opt the activity of a host protease to subvert peptide-based innate immune defense.

SUMMARY

The bacterial pathogen Group A Streptococcus (GAS) colonizes epithelial and mucosal surfaces and can cause a broad spectrum of human disease. Through the secreted plasminogen activator streptokinase (Ska), GAS activates human plasminogen into plasmin and binds it to the bacterial surface. The resulting surface plasmin protease activity has been proposed to play a role in disrupting tissue barriers, promoting invasive spread of the bacterium. We investigated whether this surface protease activity could aid immune evasion role through degradation of the key innate antimicrobial peptide (AMP) LL-37, the human cathelicidin. Cleavage products of plasmin degraded LL-37 were analyzed by matrix-assisted laser desorption ionization mass spectrometry. Ska-deficient GAS were generated by targeted allelic exchange mutagenesis and confirmed to lack surface plasmin activity after growth in human plasma or media supplemented with plasminogen and fibrinogen. Loss of surface plasmin activity left GAS unable to efficiently degrade LL-37 and increased bacterial susceptibility to killing by the AMP. When mice infected with GAS were simultaneously treated with the plasmin inhibitor aprotinin, a significant reduction in the size of necrotic skin lesions was observed. Together these data reveal a novel immune evasion strategy of the human pathogen - co-opting the activity of a host protease to evade peptide based innate host defenses.

Group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive, human-specific pathogen responsible for over 500,000 deaths each year worldwide(1). Recently, mutations in the two-component regulatory system covR/S in strains of the globally-disseminated GAS M1T1 serotype have been associated with invasive human infections and increased virulence in murine models of infection (2-4). This mutation arises spontaneously in vivo in the murine model of GAS M1T1 necrotizing fasciitis, leading to loss
of expression of the cysteine protease SpeB and increased expression of hyaluronic acid capsule and other virulence determinants (2,3). One of the characteristics of this hypervirulent animal-passaged (AP) variant is increased ability to acquire surface plasmin activity through the secreted GAS plasmin activator streptokinase (Ska)(3,5).

Plasmin is a broad-spectrum host protease produced in the liver that is involved in fibrinolysis. It is expressed initially in a zymogen form, plasminogen, present in plasma at concentrations of approximately 1-2 µM(6). Activation of plasminogen to plasmin is a process that is tightly controlled in the host involving plasminogen activators, tPA and uPA, plasminogen activator inhibitors, PAI-1 and PAI-2, and plasmin inhibitors α2-antiplasmin and α2-macroglobulin(7). GAS, however, is able to circumvent the host regulation of plasminogen activation through the streptococcal secreted plasminogen activator, Ska(8).

Ska activates plasminogen in a manner not regulated by PAI-1 or PAI-2, nor inhibited by host factors including α2-antiplasmin(7). A Ska-plasminogen complex or Ska-fibrinogen-plasminogen complex results in an active protease that is bound to the bacterial surface through plasminogen and fibrinogen receptors(8). In the absence of the broad-spectrum secreted GAS protease SpeB, active plasmin accumulates, resulting in bacterial surface protease activity that may enable the bacteria to degrade tissue barriers, facilitating invasive spread of the pathogen(5,9,10).

We hypothesized that the ability of GAS to co-opt from the host broad-spectrum protease activity on its own surface may provide the pathogen additional virulence properties. A critical element of host innate defense at the initial focus of infection is the activity of cathelicidin antimicrobial peptide (AMP). Produced by epithelial cells such as keratinocytes and immune cells including neutrophils in response to injury or infection, cathelicidin exerts direct antibacterial activity and stimulates other components of the innate immune response(11,12); loss of cathelicidin renders animals highly susceptible to invasive infection with GAS(13) and other bacterial pathogens(14,15). In this study we investigate the effect of surface plasmin accumulation on GAS susceptibility to cathelicidin antimicrobial peptides.

**EXPERIMENTAL PROCEDURES**

**Bacterial strains, media and growth conditions.** The well-characterized animal-passaged (AP) SpeB-negative, covS mutant M1T1 strain 5448AP and its parental strain 5448 were used in this study(3). *Escherichia coli* strains MC1061 and TOP10 were used for cloning. GAS strains were grown in Todd-Hewitt broth (THB), or on Todd-Hewitt agar plates (THA), *E. coli* was grown in Luria-Bertani Broth (LB) or on Luria-Bertani agar plates (LA). For antibiotic selection, erythromycin (Em) was used at 5 µg/ml for GAS or 500 µg/ml for *E. coli*. Kanamycin was used at 50 µg/ml. Bacteria were routinely grown at 37°C unless noted otherwise.

**Allelic exchange mutagenesis.** A precise, in-frame allelic replacement of the *ska* gene with *cat* encoding chloramphenicol transferase was created in GAS WT strain 5448 using established methods(16). Briefly, an 854 bp fragment upstream of *ska* was PCR amplified with primers *ska*-upF (5'-TGTACCCGCAGTTACCTGATACCC-3') and *ska*-upRcat (5'-AGAAACCTCCTACTAAAAGTTAAG-3') the latter containing a 30 bp 5' overhang homologous to the 5' end of *cat*, and a 853 bp fragment downstream of *ska* was amplified by primers *ska*-downFc (5'-CACCAGATCTTCTAATAAGATG-3'), containing a 30-bp 5' overhang homologous to the 3' end of *cat*, and *ska*-downR (5'-TGCTACCAAGAAGCGTTGATG-3'). The upstream and downstream fragments were combined with the 650 bp *cat* gene in a fusion PCR reaction using primers *ska*-upF and *ska*-downR, creating an amplicon in which *ska* had been precisely replaced with *cat*. The resulting triple fragment was TA cloned into pCR-2.1-TOPO (Invitrogen) and subsequently digested with restriction enzymes BamHI and XbaI and ligated into the temperature sensitive vector pHY304, to generate the knockout plasmid p skaKO, then transformed into GAS strain 5448 by electroporation and transformants identified at the permissive temperature of 30°C under Em selection. Transformants were then grown at the non-permissive temperature of 37°C with Em
present to select for homologous recombination and integration of the plasmid into the genome. Single crossovers were confirmed by PCR analysis. Relaxation of the plasmid was carried out at 30°C with no antibiotic. Screening for Em-sensitive colonies was used to identify double crossover events and allelic replacement mutants were confirmed by PCR and the strain was denoted 5448Δska.

To create an animal-passaged (AP) Ska knockout, equivalent to the animal passaged covR/S mutant 5448AP, the knockout strain 5448Δska was passaged in mice. 10-week old, female CD1 mice were injected subcutaneously with 1 x 10⁸ colony forming units (cfu) of 5448Δska. At 72h post-infection, mice were sacrificed, lesions homogenized, and bacteria were plated on THA. Individual colonies were screened for cysteine protease activity to detect SpeB using the azocasein assay previously described(17). SpeB negative colonies were used for covR/S PCR and sequencing as previously described(18). A covR/S mutant was identified containing a duplication of nucleotides 1056-1078 resulting in a premature stop codon after amino acid 369. This strain was subsequently used in this study and designated 5448APΔska. Although additional mutations during animal passage cannot be ruled out entirely, we ensured that the key phenotypic changes under examination were reversed upon plasmid-based complementation. Complementation was performed by transforming 5448APΔska with the plasmid pDCerm containing the ska gene, creating the resultant strain, 5448APΔska[pSka]. All experiments involving the complemented strain were performed using 5448AP and 5448APΔska transformed with the empty vector pDCerm.

Plasminogen activation and cathelicidin cleavage. Plasminogen was activated by combining 2 µg of group C streptococcal Ska (Sigma) with 2 µg human plasminogen (Sigma) in 20 µl PBS; 2 µg human plasmin (Sigma) without streptokinase was also incubated with LL-37. For cathelicidin degradation, 32 µM human LL-37 or CRAMP (American Peptide Co.) was added and the reaction was incubated at 37°C for the specified time. Reactions were stopped by the addition of 20 µg/ml aprotinin. Samples were run on 12% Bis-Tris NuPage gels (Invitrogen) with MES buffer as per manufacturer's instructions or processed for mass spectrometry analysis.

MALDI analysis of LL37 cleavage by plasmin. Cleavage reaction samples at differential time points were prepared for MALDI-TOF analysis by mixing a 1:1 ratio with Sigma-Alrich universal MALDI matrix resuspended in 78% acetonitrile and 0.1% trifluorac. 1 µL of each mixed sample was plated on a Bruker MALDI target plate for analysis. The Bruker Microflex MALDI-TOF was calibrated at 25 ppm mass error with the Bruker Pepmix 4 standard. After calibration, each spot was analyzed using reflectron positive ionization and a laser power of 60 %. Masses that corresponded to truncated forms of LL37 and absent in the control samples were noted. Select LL37 cleavage ions were further confirmed by tandem mass spectrometry for identification purposes.

Ska western blot. Bacterial cultures were grown to mid-log phase (OD₆₀₀ = 0.4) and bacteria were pelleted by centrifugation for 10 min at 3,200 x g. Supernatants were run on 10% Bis-Tris NuPage gels (Invitrogen) in MOPS buffer as per manufacturer's instructions. Gels were transferred to nitrocellulose membranes (Invitrogen) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) as per manufacturer's instructions. Membranes were blocked overnight with 5% skim milk PBS + 0.05% Tween-20 (PBST). Membranes were incubated with polyclonal rabbit-anti-Ska antibody(5) at 1:1,000 in PBST + 0.5% skim milk for 1.5 h, washed with PBST and incubated with goat-anti-rabbit-HRP conjugate (Bio-Rad) at 1:10,000 in PBST + 0.5% skim milk for 1 h. The membrane was subsequently washed and developed using Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific).

Secreted streptokinase activity assay. Bacterial cultures were grown to mid-log phase (OD₆₀₀ = 0.4) and pelleted as described above and filter sterilized through 0.22 µm syringe driven filters. 90 µl of sterile supernatant was mixed 1:1 with 1 U/ml human plasminogen (Calbiochem) and 7 µM human fibrinogen (Calbiochem) in THB in flat bottom 96-well plates (Costar). 20 µl of 3 µM S-2251 (Chromogenix) was added and the plates incubated for 1 h at 37°C. Absorbance was then read at 405 nm. 1 µg of group C Ska (Sigma) was used as a positive control. Assays were performed in triplicate and the data are presented as mean ± standard deviation.
Blood collection and plasma preparation. Blood was collected from healthy volunteers under informed consent by venipuncture with heparin used as the anticoagulant. Plasma was obtained by centrifuged for 5 min at 1000 x g. The supernatant was subsequently centrifuged for 5 min at 3000 x g.

Surface plasmin activity assay. Bacterial cultures were grown to mid-log phase (OD600 = 0.4) in THB + 50% fresh human plasma, THB supplemented with 1 U/ml human plasminogen (Calbiochem) and 7 μM fibrinogen (Calbiochem), or THB only. Bacteria were pelleted by centrifugation for 5 min at 7000 x g. Bacterial pellets were washed with PBS and resuspended in 0.1 volume of sterile PBS. 20 μl of S-2251 (Chromogenix) was added to 180 μl of bacteria in flat bottom 96-well plates (Costar) and incubated for 4 h at 37°C. Absorbance was read at 405 nm. Assays were performed in triplicate and the data are presented as mean ± standard deviation.

Degradation of LL-37 in bacterial supernatants. Bacteria were grown to mid-log phase (OD600 = 0.4) in THB supplemented with plasminogen and fibrinogen as described above. The presence of plasmin activity at the bacterial surface was confirmed as described above. Bacteria were incubated with 10 μg of LL-37 at 37°C for 1 h. Bacteria were then pelleted as above and the supernatant collected to screen for LL-37. Prior to SDS-PAGE and western blot analysis, supernatants were concentrated by tri-chloro acetic acid (TCA) precipitation. An equal volume of 10% TCA was added to supernatants and incubated on ice for 20 min. Following centrifugation at 7000 x g, the protein pellet was washed with 100% ethanol, and allowed to air dry. The protein pellet was then resuspended in 40 μl of 100 mM Tris-Cl (pH 7.6) and electrophoresed as described above. Proteins were transferred to nitrocellulose membrane using a Bio-Rad Trans-Blot apparatus (Bio-Rad, Hercules, CA, USA). Following protein transfer, membranes were blocked for 1 h at room temperature with PBS/1% skim milk. Membranes were then incubated with goat-anti-LL37 (Eurogentec, Belgium) diluted 1 in 500 in PBS/1% skim milk), followed by rabbit anti-goat IgG HRP diluted 1 in 1000 in PBS/1% skim milk. Excess secondary Ab was removed by three PBS washes for 10 min each and all blots developed in a solution of 100 mM Tris-HCl (pH 7.6) containing 1.4 mM diaminobenzidine and 0.06% (v/v) hydrogen peroxide.

Surface degradation of LL-37. Bacteria were grown to mid-log phase (OD600 = 0.4) in THB supplemented with plasminogen and fibrinogen as described above. Bacteria were centrifuged for 5 min at 7000 x g and resuspended in 0.1 volume of sterile PBS. Bacteria were incubated at 37°C and reactions were stopped at desired timepoints by the addition of aprotinin at final concentration of 20 μg/ml. Bacteria were then pelleted as above and resuspended in 100 mM glycine (pH 2.0) to elute proteins bound to the bacterial surface. After 30 min incubation at room temperature, 0.1 volume of 1.0 M Tris-HCl (pH 9.0) was added to neutralize the solution. Bacteria were pelleted as above and supernatants were run on 12% Bis-Tris NuPage gels (Invitrogen) in MES buffer as per manufacturer's instructions.

LL-37 minimum inhibitory concentration (MIC) testing and killing kinetic assay. Bacterial cultures were grown to mid-log phase (OD600 = 0.4) in PBS + 50% THB supplemented with 1 U/ml human plasminogen (Calbiochem) and 7 μM human fibrinogen (Calbiochem). Bacteria were then diluted 1:1000 in the same media and added to LL-37 (American Peptide Co.) at concentrations of 0–8 μM in 1 μM increments in flat bottom 96-well plates (Costar) and incubated for 24 h at 37°C. Aprotinin was added to relevant cultures at a final concentration of 2 μg/ml 10 min prior to addition of LL-37. MIC was determined as the lowest concentration at which no growth was observed by absorbance at 600 nm. Assays were performed in triplicate and where there was variation between replicates, the data are presented as a range. For killing kinetics, bacteria were prepared as above and LL-37 added at a final concentration of 4 μM in siliconized tubes. Tubes were incubated at 37°C with rotation, aliquots were taken at specified timepoints and serially diluted for enumeration of cfu. Statistical significance was determined by student's t-test at each timepoint. Assays were performed in triplicate and the data are presented as mean ± standard deviation.

Murine infection model. Bacteria were grown to mid-log phase in THB supplemented with human plasminogen and fibrinogen as described above. Bacteria were then washed with sterile PBS and resuspended to 1 x 107 cfu/ml in PBS...
containing 1 U/ml human plasminogen (Calbiochem) and 7 μM human fibrinogen (Calbiochem) with or without 20 μg/ml aprotinin. 1 x 10^6 cfu in 100 μl volume was injected into the flank of 10 week old, female CD1 mice. Pictures of mice were taken daily and lesion area was calculated using imageJ software. Statistical significance was determined by two-way anova. Each data point represents one lesion, n=9 for each group.

Ethics approvals. Permission to obtain human blood and undertake animal experiments was obtained from University of California, San Diego. Human volunteers provided informed consent before blood samples were obtained.

RESULTS

Ska-activated plasmin degrades LL-37. Ska-activated plasmin as well as purified human plasmin was observed to degrade the human cathelicidin AMP, LL-37 (Fig. 1a). No degradation of LL-37 was observed in the absence of either Ska or plasmin. A previous study of LL-37 degradation by cutaneous host proteases (e.g. kallikreins) identified a range of degradation products some retaining and some losing antimicrobial activity(19). To elucidate the plasmin cleavage products of LL-37, we incubated Ska-activated plasmin with purified LL-37 for varying times between 0 and 120 min (Fig. 1b). Reactions were then analysed by MALDI-TOF mass spectrometry. Degradation products of LL-37 were observed beginning as early as 1 min incubation time (Fig 1c). Previously described inactive fragments LLGDFFR and IKDFLRNLVPRTES were identified, as well as a fragment with known antimicrobial activity, KSKEKIGKEFRIVQRIKDFLRNLVPRTES, which was present at 1 min incubation but was not detectable after 120 min. The previously undescribed fragments RIVQRIKDFLRNLVPRTES and DFLRNLVPRTES were also observed and still detectable after 120 min. Since the exact contribution of a dynamic mixture of degradation products to antimicrobial activity over time was uncertain, further analysis of the interaction between plasmin accumulating bacteria and LL-37 was needed.

Characterization of Ska knockout GAS. To study the role of plasmin in GAS resistance to cathelicidin antimicrobial peptides, we created a precise, in-frame allelic replacement knockout of Ska in hypervirulent, SpeB negative, covS mutant GAS generated by animal passage and characteristic of the human invasive GAS M1T1 genotype/phenotype(2-4). Western blot analysis showed the presence of Ska in the supernatants from wild-type (WT) strain 5448AP, but not from the knockout strain (5448APΔska), from here on referred to as WT and Δska, respectively (Fig. 2a). Empty vector controls, containing the plasmid pDCerm showed similar levels of expression to their parental strains. Ska expression was restored in the plasmid complemented strain, Δska[pSka]. Ska activity was observed in the supernatants of WT GAS (Fig. 2b) and the WT strain accumulated surface plasmin activity when grown in fresh human plasma or in THB supplemented with human plasminogen and fibrinogen (Fig. 2c). To avoid the possible confounding influence of other plasma proteins, subsequent experiments were performed in THB supplemented with human plasminogen and fibrinogen.

Surface associated plasmin degrades LL-37. After allowing bacteria to accumulate surface plasmin activity by growth in the presence of human plasminogen and fibrinogen, we demonstrated that these bacteria are able to degrade LL-37 in a manner dependent on the expression of Ska (Fig 2d). Since LL-37 targets the bacterial cell wall to exert its antimicrobial activity, we further investigated whether surface plasmin could degrade LL-37 peptide associated with the bacterial surface. Bacteria allowed to accumulate surface plasmin activity were incubated with LL-37, and after washing away unbound LL-37, a low pH buffer was used to elute surface bound LL-37. Whereas Ska-expressing WT GAS showed reduced levels of intact LL-37 on their surface over time, the level of LL-37 bound to Δska mutant bacteria remained relatively constant (Fig. 2e). While it is possible that other factors may play a role in degradation of LL-37 over this time period, it is apparent from the data presented in Fig. 2e that surface acquired plasmin is the major contributor in this assay.

Surface associated plasmin increases resistance to LL-37. To determine the physiological relevance of GAS surface plasmin cleavage of cathelicidin, we conducted LL-37 sensitivity testing. After growth in media...
supplemented with plasminogen and fibrinogen to allow accumulation of surface plasmin activity, Ska-expressing WT GAS exhibited increased minimum inhibitory concentrations (MIC) for LL-37 compared to the Δska mutant (Fig 3a). Ska-expressing WT bacteria also had significantly increased survival vs. the isogenic Δska mutant in an LL-37 kinetic killing assay (Fig. 3b). These findings show that accumulation of surface plasmin, activated by Ska, provides GAS with increased resistance to LL-37 cathelicidin antimicrobial peptides.

**Plasmin inhibition reduces virulence in vivo.** To study the effect of plasmin inhibition in vivo, we utilized a murine model of necrotizing fasciitis in which cathelicidin antimicrobial peptides have been shown to be abundantly expressed (20). Ska-activated plasmin was confirmed to degrade the murine cathelicidin, CRAMP, *in vitro* (Fig. 4a). Since Ska activity is specific to human plasminogen and not murine plasminogen, GAS were allowed to accumulate surface plasmin activity during growth and bacteria were co-administered with human plasminogen and fibrinogen, with or without addition of the plasmin inhibitor aprotinin. Significantly smaller lesions were observed when plasmin acquisition was absent, either in the Ska-knockout strain or with the addition of aprotinin (Fig. 4b), demonstrating a potential therapeutic benefit of plasmin inhibition in restricting GAS proliferation.

**DISCUSSION** The ability of GAS to activate plasmin through Ska and bind the active protease to the bacterial surface has been known for some time (8,9), with potential contributions to tissue barrier disruption and invasive spread of the bacterium (5,9). In this study, we demonstrate the ability of surface acquired plasmin activity to degrade host cathelicidin antimicrobial peptides.

Cathelicidin peptides serve a critical front line role in mammalian innate immunity against invasive bacterial infection as first demonstrated in murine model of GAS infection: cathelicidin-deficient mice are more susceptible to invasive GAS infection (13) and overexpression of an additional (porcine) cathelicidin in mice provides increased resistance (21). The invasive MIT1 clone of GAS demonstrates increased resistance to cathelicidin AMPs when compared to other GAS strains (22), which may in part be attributable to cathelicidin-binding properties of the M1 protein hypervariable domain (22) or protein SIC uniquely expressed only in M1 and M57 strains (23). Upon selection of the covS mutations associated with shift to invasive infection (2,4), GAS increased expression of hyaluronic acid capsule that can impair cathelicidin killing (17) and accumulates more plasmin activity on its surface (5). Here we show that the co-optation of this host protease activity represents another important cathelicidin resistance phenotype of the globally disseminated hyperinvasive MIT1 GAS clone.

Plasmin is an important host factor involved in fibrinolysis and tissue remodeling following injury (24). Because of its potent proteolytic activity, plasmin activation is tightly regulated under normal conditions (6). GAS secreted Ska is able to activate plasmin independent of host plasmin activators (8), creating the opportunity for active plasmin to function in environments that are not present in an uninfected host.

Cathelicidin has previously been shown to influence the expression of Ska through the two-component regulatory system covR/S (25), however, no relationship between Ska expression and resistance to cathelicidin has been shown. The genetically unrelated plasmin activator of *Staphylococcus aureus*, staphylokinase, can increase resistance to human defenses through direct binding of the AMP by staphylokinase, independent of its plasmin-activating capacity (26). In contrast to these findings, here we showed that Ska-activated plasmin increases resistance to cathelicidin antimicrobial peptides by virtue of its plasmin protease activity. Interestingly, cathelicidin has been shown to increase staphylokinase-dependent fibrinolysis by plasmin (27). It is not known whether staphylokinase activation of plasmin results in increased resistance of *S. aureus* to cathelicidin or whether cathelicidin can influence the fibrinolytic capacity of Ska-activated plasmin.

We demonstrated the therapeutic potential of plasmin inhibition for reducing the severity of GAS subcutaneous infections. Blocking the ability of GAS to acquire Ska-activated plasmin activity on its surface, either by genetic manipulation of Ska or by inhibition of plasmin activity with aprotinin, significantly reduced virulence in a murine infection model. Pharmacological
Streptokinase-activated plasmin degrades cathelicidin AMPs

inhibition of Ska in combination with other virulence determinants has recently been shown to reduce GAS virulence in mice(28). Our data has shown that inhibition of plasmin protease activity (the critical effector mechanism of Ska) is sufficient to reduce GAS virulence in a murine skin infection model.

In summary, these data present a new look at a GAS virulence factor. In addition to providing GAS with an ability to spread through tissue barriers, Ska also provides the bacterium with an immune evasion tool. While there is no current inhibitor of Ska in clinical development, plasmin protease activity itself provides a valid target for novel GAS therapeutics.

REFERENCES

1. Carapetis, J. R., Steer, A. C., Mulholland, E. K., and Weber, M. (2005) Lancet Infect Dis 5, 685-694
2. Sumby, P., Whitney, A. R., Graviss, E. A., DeLeo, F. R., and Musser, J. M. (2006) PLoS Pathogens 2, e5
3. Walker, M. J., Hollands, A., Sanderson-Smith, M. L., Cole, J. N., Kirk, J. K., Henningham, A., McArthur, J. D., Dinkla, K., Aziz, R. K., Kansal, R. G., Simpson, A. J., Buchanan, J. T., Chhatwal, G. S., Kotb, M., and Nizet, V. (2007) Nat Med 13, 981-985
4. Cole, J. N., Barnett, T. C., Nizet, V., and Walker, M. J. (2011) Nat Rev Microbiol 9, 724-736
5. Cole, J. N., McArthur, J. D., McKay, F. C., Sanderson-Smith, M. L., Cork, A. J., Ranson, M., Rohde, M., Itzek, A., Sun, H., Ginsburg, D., Kotb, M., Nizet, V., Chhatwal, G. S., and Walker, M. J. (2006) FASEB J 20, 1745-1747
6. Ponting, C. P., Marshall, J. M., and Cederholm-Williams, S. A. (1992) Blood Coagul Fibrinolysis 3, 605-614
7. Parry, M. A., Zhang, X. C., and Bode, I. (2000) Trends Biochem Sci 25, 53-59
8. Walker, M. J., McArthur, J. D., McKay, F., and Ranson, M. (2005) Trends Microbiol 13, 308-313
9. Lottenberg, R., Minning-Wenz, D., and Boyle, M. D. (1994) Trends Microbiol 2, 20-24
10. Sanderson-Smith, M. L., Dinkla, K., Cole, J. N., Cork, A. J., Maamary, P. G., McArthur, J. D., Chhatwal, G. S., and Walker, M. J. (2008) FASEB J 22, 2715-2722
11. Durr, U. H., Sudheendra, U. S., and Ramamoorthy, A. (2006) Biochim Biophys Acta 1758, 1408-1425
12. Zanetti, M. (2004) J Leukoc Biol 75, 39-48
13. Nizet, V., Ohtake, T., Lauth, X., Trowbridge, J., Rudisill, J., Dorschner, R. A., Pestonjamasp, V., Piraino, J., Huttner, K., and Gallo, R. L. (2001) Nature 414, 454-457
14. Bergman, P., Johansson, L., Wan, H., Jones, A., Gallo, R. L., Gudmundsson, G. H., Hokfelt, T., Jonsson, A. B., and Agerberth, B. (2006) Infect Immun 74, 6982-6991
15. Chromek, M., Slamova, Z., Bergman, P., Kovacs, L., Grabacka, L., Ehren, I., Hokfelt, T., Gudmundsson, G. H., Gallo, R. L., Agerberth, B., and Brauner, A. (2006) Nat Med 12, 636-641
16. Buchanan, J. T., Simpson, A. J., Aziz, R. K., Liu, G. Y., Kristian, S. A., Kotb, M., Feramisco, J., and Nizet, V. (2006) Curr Biol 16, 396-400
17. Cole, J. N., Pence, M. A., von Kockritz-Blickwede, M., Hollands, A., Gallo, R. L., Walker, M. J., and Nizet, V. (2010) MBio 1, e00191-10
Streptokinase-activated plasmin degrades cathelicidin AMPs

18. Hollands, A., Aziz, R. K., Kansal, R., Kotb, M., Nizet, V., and Walker, M. J. (2008) PloS One 3, e4102
19. Yamasaki, K., Schaub, J., Coda, A., Lin, H., Dorschner, R. A., Schechter, N. M., Bonnart, C., Descargues, P., Hovnanian, A., and Gallo, R. L. (2006) FASEB J 20, 2068-2080
20. Dorschner, R. A., Pestonjamasp, V. K., Tamakuwala, S., Ohtake, T., Rudisill, J., Nizet, V., Agerberth, B., Gudmundsson, G. H., and Gallo, R. L. (2001) J Invest Dermatol 117, 91-97
21. Lee, P. H., Ohtake, T., Zaiou, M., Murakami, M., Rudisill, J. A., Lin, K. H., and Gallo, R. L. (2005) Proc Natl Acad Sci U S A 102, 3750-3755
22. Lauth, X., von Kockritz-Blickwede, M., McNamara, C. W., Myskowski, S., Zinkernagel, A. S., Beall, B., Ghosh, P., Gallo, R. L., and Nizet, V. (2009) J Innate Immun 1, 202-214
23. Pence, M. A., Rooijakkers, S. H., Cogen, A. L., Cole, J. N., Hollands, A., Gallo, R. L., and Nizet, V. (2010) J Innate Immun 2, 587-595
24. Collen, D. (1999) Thromb Haemost 82, 259-270
25. Gryllos, I., Tran-Winkler, H. J., Cheng, M. F., Chung, H., Bolcome, R., 3rd, Lu, W., Lehrer, R. I., and Wessels, M. R. (2008) Proc Natl Acad Sci U S A 105, 16755-16760
26. Jin, T., Bokarewa, M., Foster, T., Mitchell, J., Higgins, J., and Tarkowski, A. (2004) J Immunol 172, 1169-1176
27. Braff, M. H., Jones, A. L., Skerrett, S. J., and Rubens, C. E. (2007) J Infect Dis 195, 1365-1372
28. Sun, H., Xu, Y., Sitkiewicz, I., Ma, Y., Wang, X., Yestrepo, B. D., Huang, Y., Lapadatescu, M. C., Larsen, M. J., Larsen, S. D., Musser, J. M., and Ginsburg, D. (2012) Proc Natl Acad Sci U S A 109, 3469-3474

FOOTNOTES

AH is the recipient of a CJ Martin - Overseas Biomedical Fellowship from the National Health and Medical Research Council of Australia (NHMRC). MSS is the recipient of a Career development fellowship from the NHMRC. This work was funded through NIH grants (AI077780, AI052453, AR052728) and NHMRC Grant (635218).

FIGURE LEGENDS

Figure 1. Plasmin degradation of human cathelicidin, LL-37. A. SDS-PAGE gel showing incubation of human plasminogen (hPLG), streptokinase (ska) and purified LL-37. Human plasminogen (PLN) without streptokinase is included as a control. Arrow indicates size of full length LL-37. B. SDS-PAGE gel showing time course of Ska-activated plasmin incubated with LL-37. C. MS analysis of LL-37 cleavage products shown in panel B. Asterisks indicate [M+H]+ of LL-37 with an m/z of 4492 Da and [M+2H]2+ of LL-37 with an m/z 2247 Da. Numbers correspond to fragments identified in panel D. D. LL-37 fragments identified by MS analysis.

Figure 2. LL-37 degradation by plasmin on the bacterial surface. A. Western blot for Ska in culture supernatants. B. Ska activity assay from culture supernatants Values shown are mean ± sd. C. Plasmin activity assay on washed bacteria after growth in 50% human plasma, media supplemented with human plasminogen and fibrinogen, or media without supplementation. Values shown are mean ± sd. D. Western blot showing degradation of LL-37 in supernatants after incubation with bacteria grown in media.
supplemented with human plasminogen and fibrinogen. E. SDS-PAGE gel showing LL-37 eluted from the surface of bacteria grown in media supplemented with human plasminogen and fibrinogen.

**Figure 3.** Surface plasmin activity increases resistance to LL-37. A. LL-37 minimum inhibitory concentration assay on bacteria grown in media supplemented with human plasminogen and fibrinogen. B. LL-37 killing kinetics assay on bacteria grown in media supplemented with human plasminogen and fibrinogen. Values in all panels represent mean ± sd; * indicates $P < 0.05$.

**Figure 4.** Inhibition of plasmin reduces virulence *in vivo*. A. SDS-PAGE gel showing incubation of human plasminogen (hPLG), streptokinase (ska) and purified murine cathelicidin, CRAMP. Arrow indicates size of full length CRAMP. B. Lesion size of mice following subcutaneous infection with GAS strains grown in media supplemented with human plasminogen and fibrinogen, co-administered with or without the addition of aprotinin. Values represent mean ± sd; * indicates $P < 0.05$, ** indicates $P < 0.01$, *** indicates $P < 0.001$. 
Streptokinase-activated plasmin degrades cathelicidin AMPs

FIGURE 1

A. Plasmin cleavage of LL-37

LL-37

hPLG: - + - + - + + +
Ska: - + - + - + + +
LL-37: - - + + - + + +

B. Plasmin cleavage of LL-37

LL-37

Ctrl 0 1 5 15 30 60 120

C. Mass spectrometry

D. LL-37 cleavage products

LL-37

(1) KSKEKIGKEFKRIVQRKDFLRNLVPRTES
(2) RIVQRIKDFLRNLVPRTES
(3) IKDFLRNLVPRTES
(4) DFLRNLVPRTES
(5) LLGDFR
FIGURE 2

A Streptokinase (Ska) western blot

- Media
- WT
- Δska
- WT* Δska
- Δska +pSka

*contains empty vector (pDCerm) used in all subsequent studies

B Streptokinase activity

- Media
- WT
- Δska
- Δska +pSka
- PBS
- hPLG
- hPLG +Ska

C Surface plasmin activity

- WT
- Δska
- Δska +pSka

- 50% human plasma
- +Plg/Fn
- -Plg/Fn
- PBS hPLG hPLG +Ska

D Control
- Ctrl
- WT
- Δska

E LL-37
- WT GAS
- Δska mutant

- 1h
- 2h
- 3h
- 4h

- LL-37
FIGURE 3

A

LL-37 MIC Values

| Strain            | MIC (μM) |
|-------------------|----------|
| WT GAS            | 4        |
| Δska mutant       | 2        |
| Δska + pSka       | 5        |
| WT + aprotinin    | 2-3      |

B

LL-37 killing kinetics

Surviving bacteria (% of input cfu) vs Time (h)

- WT GAS
- Δska mutant

* indicates significant difference.
FIGURE 4

A. CRAMP degradation by plasmin

|        | hPLG | Ska | CRAMP |
|--------|------|-----|-------|
| +      | +    | -   | -     |
| -      | -    | +   | +     |
| +      | +    | +   | +     |
| -      | -    | +   | +     |
| +      | -    | -   | +     |
| +      | +    | +   | +     |

B. Mouse subcutaneous challenge

Lesion area (mm²) vs. Days of infection

- WT
- WT + aprotinin
- Δska
- Δska + aprotinin

Significance levels indicated by:
- * p < 0.05
- ** p < 0.01
- *** p < 0.001
A bacterial pathogen co-opts host plasmin to resist killing by cathelicidin antimicrobial peptides
Andrew Hollands, David Gonzalez, Emma Leire, Cortny Donald, Richard L. Gallo, Martina Sanderson-Smith, Pieter C. Dorrestein and Victor Nizet

J. Biol. Chem. published online October 4, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.404582

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts